UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices

Scientific reports, 2021-04, Vol.11 (1), p.9222-9222, Article 9222

2021

Volltextzugriff (PDF)

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

The New England journal of medicine, 2018-11, Vol.379 (21), p.2040-2051

2018

Volltextzugriff (PDF)

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

The lancet oncology, 2017-05, Vol.18 (5), p.623-630

2017

Volltextzugriff (PDF)

KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy

Annals of surgical oncology, 2010-04, Vol.17 (4), p.1168-1176

2010

Volltextzugriff (PDF)

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2010-03, Vol.28 (8), p.1351-1357

2010

Volltextzugriff (PDF)

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib

Journal of thoracic oncology, 2013-06, Vol.8 (6), p.693-702

2013

Volltextzugriff (PDF)

Abstract CT084: Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT084-CT084

2020

Volltextzugriff (PDF)

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

JTO clinical and research reports, 2021-08, Vol.2 (8), p.100205-100205, Article 100205

2021

Volltextzugriff (PDF)

Human Barrett's adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant

Stem cells and development, 2011-01, Vol.20 (1), p.11-17

2011

Volltextzugriff (PDF)

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

JTO clinical and research reports, 2023-01, Vol.4 (1), p.100431, Article 100431

2023

Volltextzugriff (PDF)

Development of a Method to Implement Whole-Genome Bisulfite Sequencing of cfDNA from Cancer Patients and a Mouse Tumor Model

Frontiers in genetics, 2018-01, Vol.9, p.6-6

2018

Volltextzugriff (PDF)

Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: observations from a US regional analysis of the GIDEON registry

The American journal of surgery, 2017-04, Vol.213 (4), p.688-695

2017

Volltextzugriff (PDF)

Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer

Drugs (New York, N.Y.), 2014-03, Vol.74 (4), p.403-413

2014

Volltextzugriff (PDF)

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

Journal of clinical oncology, 2017-12, Vol.35 (34), p.3823-3829

2017

Volltextzugriff (PDF)

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

Lung cancer (Amsterdam, Netherlands), 2019-09, Vol.135, p.188-195

2019

Volltextzugriff (PDF)

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Journal of thoracic oncology, 2020-10, Vol.15 (10), p.1657-1669

2020

Volltextzugriff (PDF)

Phase II Study of a Liposome-Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally and Pathologic Response Rates in Patients With Malignant Pleural Mesothelioma

Journal of clinical oncology, 2005-05, Vol.23 (15), p.3495-3501

2005

Volltextzugriff (PDF)

Schedule-Dependent Interaction between the Proteosome Inhibitor Bortezomib and the EGFR-TK Inhibitor Erlotinib in Human Non-small Cell Lung Cancer Cell Lines

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.715-721

2007

Volltextzugriff (PDF)

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Journal of clinical oncology, 2021-07, Vol.39 (21), p.JCO2003579-2338

2021

Volltextzugriff (PDF)

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.1718-1732

2021

Volltextzugriff (PDF)

Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer: Clinical Outcomes in Wild-Type Epidermal Growth Factor Receptor Patients

Drugs (New York, N.Y.), 2012-06, Vol.72 (Suppl 1), p.11-19

2012

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Cancer, 2020-11, Vol.126 (22), p.4867-4877

2020

Volltextzugriff (PDF)

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407

Journal of thoracic oncology, 2021-11, Vol.16 (11), p.1883-1892

2021

Volltextzugriff (PDF)

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.162-168

2021

Volltextzugriff (PDF)

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

The lancet respiratory medicine, 2019-04, Vol.7 (4), p.347-357

2019

Volltextzugriff (PDF)

1 – 25 von 111

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(99)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(53)
Life Sciences & Biomedicine
(52)
Humans
(39)
Oncology
(39)
Female
(22)
Male
(22)
Middle Aged
(22)
Aged
(18)
Lung Neoplasms - Drug Therapy
(17)
Pembrolizumab
(15)
Respiratory System
(15)
Aged, 80 And Over
(14)
Chemotherapy
(14)
Adult
(13)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(13)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Lung Neoplasms - Pathology
(11)
Patients
(10)
Immunotherapy
(9)
Lung Cancer
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib

Abstract CT084: Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC

Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

Human Barrett's adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

Development of a Method to Implement Whole-Genome Bisulfite Sequencing of cfDNA from Cancer Patients and a Mouse Tumor Model

Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: observations from a US regional analysis of the GIDEON registry

Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Phase II Study of a Liposome-Entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally and Pathologic Response Rates in Patients With Malignant Pleural Mesothelioma

Schedule-Dependent Interaction between the Proteosome Inhibitor Bortezomib and the EGFR-TK Inhibitor Erlotinib in Human Non-small Cell Lung Cancer Cell Lines

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer: Clinical Outcomes in Wild-Type Epidermal Growth Factor Receptor Patients

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407

Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study

Suchergebnisse filtern